This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (69)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Pediatrics  • Pediatrics, Other  • Drug Therapy  • Pediatric Dosing  • Alert me on articles by topic  Social Bookmarking   What's this?

Improving the Safety and Efficacy of Pediatric Therapies

Rosemary Roberts, MD; William Rodriguez, MD; Dianne Murphy, MD; Terrie Crescenzi, RPh

JAMA. 2003;290:905-911.

Context  Approximately 50% to 75% of drugs used in pediatric medicine have not been studied adequately to provide appropriate labeling information. In 1997, Congress passed the Food and Drug Administration Modernization Act (FDAMA), which encouraged pediatric drug development by providing an incentive in the form of additional marketing exclusivity.

Objective  To identify new drug labeling information from pediatric studies submitted to the FDA in response to written requests.

Design and Setting  Between July 1998 and April 1, 2002, the FDA requested studies on 242 drugs, and 53 drugs were granted exclusivity. As of January 2003, 49 drugs have new labels. Data from the studies of the first 33 drugs with new pediatric information on the label as of April 2002 are included. Significant labeling information was analyzed along with baseline data and types of studies requested.

Main Outcome Measures  Safety data and pediatric information for labeled drugs.

Results  There were 53 studies for 33 drug products, 12 (23%) were evaluated for safety only; 23 (43%), safety and efficacy; and 18 (34%), pharmacokinetics and/or pharmacodynamics. Significant new dosing and/or safety information was identified for 12 (36%) drugs. New dosing information was determined for 7 of these drugs. Safety information was defined for gabapentin, propofol, sevoflurane, the combination of ribavirin and interferon alfa-2b, and various betamethasone-containing dermatologic preparations. There was a higher percentage of deaths reported with patients who received propofol compared with controls in the pediatric intensive care unit. Seizures were seen in patients administered sevoflurane. Patients receiving a combination of ribavirin and interferon alfa-2b experienced an increased incidence of suicidal ideation when compared with adults. An unexpectedly high percentage of those receiving betamethasone-containing dermatologic preparations had documented hypopituitary-adrenal axis suppression.

Conclusion  The FDAMA has stimulated pediatric clinical studies resulting in improved understanding of the pharmacokinetics of drugs prescribed in pediatric medicine, important dose changes, and improved safety for children taking certain drugs.

Author Affiliations: Office of Counter-Terrorism and Pediatric Drug Development, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Ensuring Safe and Effective Medications for Children
Peter P. Budetti
JAMA. 2003;290(7):950-951.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Growth-Attenuation Therapy: Principles for Practice
Allen et al.
Pediatrics 2009;123:1556-1561.
ABSTRACT | FULL TEXT  

Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes
Resche-Rigon et al.
Clin Trials 2008;5:595-606.
ABSTRACT  

Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity
Smith et al.
Pediatrics 2008;122:e628-e633.
ABSTRACT | FULL TEXT  

Pediatric Antihypertensive Trial Failures: Analysis of End Points and Dose Range
Benjamin et al.
Hypertension 2008;51:834-840.
ABSTRACT | FULL TEXT  

Improving Pediatric Dosing Through Pediatric Initiatives: What We Have Learned
Rodriguez et al.
Pediatrics 2008;121:530-539.
ABSTRACT | FULL TEXT  

Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial
Li et al.
Circulation 2008;117:553-559.
ABSTRACT | FULL TEXT  

Children's and Their Parents' Views on Facing Research Risks for the Benefit of Others
Wendler and Jenkins
Arch Pediatr Adolesc Med 2008;162:9-14.
ABSTRACT | FULL TEXT  

Issues in Imaging-Guided Tumor Ablation in Children Versus Adults
Brown and vanSonnenberg
Am. J. Roentgenol. 2007;189:626-632.
ABSTRACT | FULL TEXT  

The EU's new paediatric medicines legislation: serving children's needs?
Permanand et al.
Arch. Dis. Child. 2007;92:808-811.
ABSTRACT | FULL TEXT  

Off-label Drug Use in Hospitalized Children
Shah et al.
Arch Pediatr Adolesc Med 2007;161:282-290.
ABSTRACT | FULL TEXT  

Limitations of Clinical Trials in Sickle Cell Disease: A Case Study of the Multi-center Study of Hydroxyurea (MSH) Trial and the Stroke Prevention (STOP) Trial
DeBaun and Field
ASH Education Book 2007;2007:482-488.
ABSTRACT | FULL TEXT  

Pill Swallowing Ability and Training in Children 6 to 11 Years of Age
Meltzer et al.
CLIN PEDIATR 2006;45:725-733.
ABSTRACT  

Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
Benjamin et al.
JAMA 2006;296:1266-1273.
ABSTRACT | FULL TEXT  

Patterns of drug utilization in a neonatal intensive care unit.
Warrier et al.
J Clin Pharmacol 2006;46:449-455.
ABSTRACT | FULL TEXT  

FDA Labeling Status of Pediatric Medications
Yoon et al.
CLIN PEDIATR 2006;45:75-77.
 

Drug Utilization in the Pediatric Intensive Care Unit: Monitoring Prescribing Trends and Establishing Prioritization of Pharmacotherapeutic Evaluation of Critically Ill Children
Zuppa et al.
J Clin Pharmacol 2005;45:1305-1312.
ABSTRACT | FULL TEXT  

Drug administration errors and their determinants in pediatric in-patients
Prot et al.
Int J Qual Health Care 2005;17:381-389.
ABSTRACT | FULL TEXT  

Quantifying the Federal Minimal Risk Standard: Implications for Pediatric Research Without a Prospect of Direct Benefit
Wendler et al.
JAMA 2005;294:826-832.
ABSTRACT | FULL TEXT  

Children Experience Cognitive Decline Despite Reversal of Brain Atrophy One Year After Resolution of Cushing Syndrome
Merke et al.
J. Clin. Endocrinol. Metab. 2005;90:2531-2536.
ABSTRACT | FULL TEXT  

Prevalence of Atypical Antipsychotic Drug Use Among Commercially Insured Youths in the United States
Curtis et al.
Arch Pediatr Adolesc Med 2005;159:362-366.
ABSTRACT | FULL TEXT  

Polypharmacy: A New Paradigm for Quality Drug Therapy in the Elderly?
Gurwitz
Arch Intern Med 2004;164:1957-1959.
FULL TEXT  

Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders
Wheless and Bourgeois
J Child Neurol 2004;19:S39-S48.
ABSTRACT  

Determining the Appropriateness of Including Children in Clinical Research: How Thick Is the Ice?
Sugarman
JAMA 2004;291:494-496.
FULL TEXT  

Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders
Wheless and Bourgeois
J Child Neurol 2004;19:S39-S48.
ABSTRACT  

FDA law improves safety of pediatric medicines
Kemp
AAP News 2003;23:146-146.
FULL TEXT  

Ensuring Safe and Effective Medications for Children
Budetti
JAMA 2003;290:950-951.
FULL TEXT